DCAT’s 2026 Study: 
Creating Value Beyond Product and Price in the Pharma Customer-Supplier Relationship

About the Study

The Drug, Chemical & Associated Technologies Association (DCAT) and its Research & Benchmarking Committee is pleased to make available to DCAT Member Companies its latest study, Creating Value Beyond Product and Price in the Pharma Customer-Supplier Relationship.

In a highly competitive environment, providing value beyond core deliverables of product and price is crucial for CDMOs and materials suppliers to gain and maintain an edge with their bio/pharma customers, but do bio/pharma companies and their suppliers agree on what constitutes value-added enhancements?

Gain valuable insights from the study, which provides a “buy-and-sell-side view” on: 

• What Constitutes Value Creation? Are there particular services or situations for which value-added enhancements are more likely to be offered than for other services? Is there a trend to offer value-adding services more frequently? Less frequently? 

• How is Value Creation Measured? When value-adding enhancements are proposed during the sourcing/procurement process, how formally are they evaluated? Is there a formal cost/benefit analysis done or is the evaluation more subjective?